1684 related articles for article (PubMed ID: 30208379)
61. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
Ueki M; Kobayashi I; Takezaki S; Tozawa Y; Okura Y; Yamada M; Kuwana M; Ariga T
Mod Rheumatol; 2019 Mar; 29(2):351-356. PubMed ID: 29532710
[TBL] [Abstract][Full Text] [Related]
62. Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis.
Fernandez C; Bardin N; De Paula AM; Salort-Campana E; Benyamine A; Franques J; Schleinitz N; Weiller PJ; Pouget J; Pellissier JF; Figarella-Branger D
Medicine (Baltimore); 2013 Jan; 92(1):15-24. PubMed ID: 23269233
[TBL] [Abstract][Full Text] [Related]
63. Autoantibodies: Pathogenic or epiphenomenon.
Galindo-Feria AS; Wang G; Lundberg IE
Best Pract Res Clin Rheumatol; 2022 Jun; 36(2):101767. PubMed ID: 35810122
[TBL] [Abstract][Full Text] [Related]
64. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.
Kao AH; Lacomis D; Lucas M; Fertig N; Oddis CV
Arthritis Rheum; 2004 Jan; 50(1):209-15. PubMed ID: 14730618
[TBL] [Abstract][Full Text] [Related]
65. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy.
Stenzel W; Preuße C; Allenbach Y; Pehl D; Junckerstorff R; Heppner FL; Nolte K; Aronica E; Kana V; Rushing E; Schneider U; Claeys KG; Benveniste O; Weis J; Goebel HH
Neurology; 2015 Mar; 84(13):1346-54. PubMed ID: 25746564
[TBL] [Abstract][Full Text] [Related]
66. Inflammatory muscle disease - An update.
Baig S; Paik JJ
Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101484. PubMed ID: 32046904
[TBL] [Abstract][Full Text] [Related]
67. [New insights of myositis-specific and -associated autoantibodies in juvenile and adult type myositis].
Váncsa A; Dankó K
Orv Hetil; 2016 Jul; 157(30):1179-84. PubMed ID: 27452067
[TBL] [Abstract][Full Text] [Related]
68. Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort.
Loganathan A; Gupta L; Rudge A; Lu H; Bowler E; McMorrow F; Naveen R; Anuja AK; Agarwal V; McHugh N; Tansley S
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38479813
[TBL] [Abstract][Full Text] [Related]
69. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.
Yang H; Peng Q; Yin L; Li S; Shi J; Zhang Y; Lu X; Shu X; Zhang S; Wang G
Arthritis Res Ther; 2017 Nov; 19(1):259. PubMed ID: 29178913
[TBL] [Abstract][Full Text] [Related]
70. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre.
Loarce-Martos J; Lilleker JB; Parker M; McHugh N; Chinoy H
Rheumatology (Oxford); 2021 Jul; 60(7):3398-3403. PubMed ID: 33367878
[TBL] [Abstract][Full Text] [Related]
71. Current Classification and Management of Inflammatory Myopathies.
Schmidt J
J Neuromuscul Dis; 2018; 5(2):109-129. PubMed ID: 29865091
[TBL] [Abstract][Full Text] [Related]
72. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A
Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491
[TBL] [Abstract][Full Text] [Related]
73. Idiopathic inflammatory myopathies with anti-mitochondrial antibodies: Clinical features and treatment outcomes in a Chinese cohort.
Hou Y; Liu M; Luo YB; Sun Y; Shao K; Dai T; Li W; Zhao Y; Yan C
Neuromuscul Disord; 2019 Jan; 29(1):5-13. PubMed ID: 30579751
[TBL] [Abstract][Full Text] [Related]
74. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.
Johnson C; Connors GR; Oaks J; Han S; Truong A; Richardson B; Lechtzin N; Mammen AL; Casciola-Rosen L; Christopher-Stine L; Danoff SK
Respir Med; 2014 Oct; 108(10):1542-8. PubMed ID: 25269710
[TBL] [Abstract][Full Text] [Related]
75. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.
Shah M; Mamyrova G; Targoff IN; Huber AM; Malley JD; Rice MM; Miller FW; Rider LG;
Medicine (Baltimore); 2013 Jan; 92(1):25-41. PubMed ID: 23263716
[TBL] [Abstract][Full Text] [Related]
76. Comparison of the 2017 EULAR/ACR Criteria with Clinicoserologic Criteria for the Classification of Idiopathic Inflammatory Myopathies in Korean Patients.
Chung SW; Yoo IS; Kim J; Kang SW; Kwon M; Joung CI; Choi IA; Chang SH; Kang MI; Hong SJ; Lee YA
Yonsei Med J; 2021 May; 62(5):424-430. PubMed ID: 33908213
[TBL] [Abstract][Full Text] [Related]
77. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G; Antonini G; Garibaldi M
Autoimmun Rev; 2022 Feb; 21(2):102993. PubMed ID: 34798316
[TBL] [Abstract][Full Text] [Related]
78. [Polymyositis, dermatomyositis and inclusion body myositis, nosological aspects].
Eymard B
Presse Med; 2003 Oct; 32(35):1656-67. PubMed ID: 14631270
[TBL] [Abstract][Full Text] [Related]
79. Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis.
Gherardi RK
Presse Med; 2011 Apr; 40(4 Pt 2):e209-18. PubMed ID: 21376512
[TBL] [Abstract][Full Text] [Related]
80. Clinical significance of myositis-specific autoantibodies.
Nakashima R
Immunol Med; 2018 Sep; 41(3):103-112. PubMed ID: 30938275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
